Prior to blogs or GitHub existing, people used to just upload the things that they'd been working on to their personal websites. This site was created with the same aim way back in 2003 (long before Facebook and even MySpace!) The name comes from the sample text in a logo design template in the GIMP. It's a little bit silly, but we could all do with a bit more silliness.

This site largely consists of research publications, where I (Robert McLeay) am an author, software projects that hopefully are of use to others, and notes on various topics (such as building a boat, connecting a garage door to Siri, or porting C++ code from unix to windows). So if you find something useful to you, I'm glad to have helped.

Over the years, I have worked in a range of fields including IT, bioinformatics/genomics (where I completed a PhD applying machine learning to genomics), and what could be called applied pharmacology - building a successful medtech startup company with a software based medical device (DoseMe) — from writing the first line of code to exit via acquisition. Currently, I am completing a medical degree, participating in research, and assisting startup companies, particularly in healthcare - such as Atidia.

At DoseMe, I founded and led development of precision dosing and dose individualisation software for doctors, pharmacists and other healthcare providers, at both the bedside (DoseMeRx) and whole-of-hospital level (DoseMe Cohere). At the end of 2019 when I left DoseMe to more experienced hands, DoseMeRx provided model informed precision dosing for 40+ medications such as vancomycin to approximately 150 hospitals, predominantly across the United States, but also in several European countries, and Australia.

In January 2019 DoseMe was acquired by Tabula Rasa Healthcare (NASDAQ: TRHC), adding a new head office in Moorestown NJ, with existing staff remaining present in Texas, and maintaining (and growing) our Australian office in Brisbane. I resigned at the end of the 2019 year, confident that DoseMe is in safe hands for its continued growth and expansion.

As of 2021, DoseMe supports over 7,000 clinician users, contains 42 drug models ranging from antibiotics to transplant medicines to chemotherapy, and to date has calculated over 1.4 million medication doses. DoseMe has had significant impact on patient outcomes - raising the proportion of vancomycin patients dosed safely and effectively by approximately 50% (IDWeek 2019). Hospitals using DoseMe have been able to demonstrate reducing the incidence of antibiotic-associated acute kidney injury (AKIs) by 83%. Reflecting on my ICU term as a medical student, AKIs in patients receiving vancomycin were incredibly common - and sadly, the vast majority are likely avoidable.

On a lighter note, I enjoy flying (models and general aviation), playing bass guitar and piano, and sailing. If you wish to get in touch, feel free to email me.